JNJ
A warmer handoff from Argus
Argus just raised its price target on Johnson & Johnson to $355 from $340 and left the Buy rating untouched. Translation: the stock’s not just getting a pat on the back — it’s getting a slightly bigger runway.
Why the bull case is sticking
The firm said the recent re-rating in J&J shares makes sense, especially with earnings prospects improving as capital markets activity rebounds. In plain English, investors are being asked to believe the old giant still has some new tricks.
What this means for your portfolio
A price-target hike doesn’t magically move a stock by itself, but it does matter when it comes from a shop that thinks the underlying earnings picture is getting better. For a name like J&J — the kind of company that’s supposed to be boring in the best possible way — incremental optimism can keep valuation support from slipping.
Big picture
This is less “new era” and more “the market’s getting comfortable paying up again.” If J&J keeps delivering on earnings and the healthcare machine stays humming, analysts may keep nudging their targets higher instead of asking what’s wrong with the story.